맞춤형 의료 시장 예측(-2034년) : 제품, 기술, 용도, 최종사용자, 지역별 분석

According to Stratistics MRC, the Global Personalized Medicine Market is accounted for $671.3 billion in 2026 and is expected to reach $1318.1 billion by 2034 growing at a CAGR of 8.8% during the forecast period. Personalized medicine is a modern healthcare method that customizes prevention, diagnosis, and treatment according to an individual's unique biological and environmental profile. It integrates genetic information, lifestyle habits, and clinical data to deliver more accurate and effective medical solutions. Through tools like genomic analysis, predictive modeling, and biomarker evaluation, doctors can identify health risks earlier and select therapies with greater precision. This reduces ineffective treatments and adverse reactions while improving recovery rates. By moving away from generalized treatment approaches, personalized medicine enhances patient care quality, supports better decision-making, and promotes a more efficient, data-driven healthcare system focused on individual needs.

According to the U.S. National Institutes of Health (NIH), the All of Us Research Program has enrolled over 873,000 participants as of 2026, with 414,000 whole-genome sequences generated.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

The rising incidence of chronic illnesses including cancer, diabetes, heart diseases, and respiratory disorders is significantly boosting the personalized medicine market. These conditions require long-term care and individualized treatment strategies, which conventional approaches often fail to deliver effectively due to differences in patient response. Personalized medicine addresses this gap by offering customized therapies based on genetic makeup, environment, and lifestyle patterns. This leads to improved disease control and fewer complications. Increasing life expectancy, changing dietary habits, and sedentary lifestyles are contributing to higher disease rates, thereby increasing the need for precise, patient-specific healthcare solutions worldwide for better long-term outcomes.

Restraint:

High cost of personalized medicine development and implementation

High expenditure associated with personalized medicine development and deployment acts as a significant market limitation. Advanced processes such as gene sequencing, molecular diagnostics, and bioinformatics require substantial financial investment. Healthcare organizations must also build specialized infrastructure and employ trained experts to interpret complex datasets. Furthermore, individualized therapies and precision drug development are more costly than conventional treatment methods. These expenses reduce affordability and restrict adoption, particularly in low and middle income regions with limited healthcare funding. Consequently, the overall expansion of personalized medicine is slowed, as many healthcare systems struggle to support the high costs involved in implementation and maintenance.

Opportunity:

Expansion of genomic research and precision diagnostics

Growing genomic research and advancements in precision diagnostics offer a strong growth opportunity for the personalized medicine market. Improvements in gene sequencing, biomarker identification, and molecular analysis are enhancing the understanding of how diseases develop at an individual level. This enables more accurate diagnostic tools and treatment plans based on a patient's genetic profile. Increased funding from public and private sectors is driving rapid innovation in this area. The expansion of large genomic databases further supports better prediction of disease risks and therapy outcomes. Overall, this trend is creating significant potential for advanced diagnostic solutions and wider adoption of precision healthcare worldwide.

Threat:

Ethical concerns and genetic discrimination risks

Ethical issues and the possibility of genetic discrimination pose a serious challenge to the personalized medicine market. Since genetic data is highly sensitive, its use raises concerns about privacy protection, consent, and possible misuse. Individuals may face discrimination from employers or insurance providers if their genetic information indicates a higher risk of diseases. This fear can reduce willingness to undergo genetic testing or share personal health data. Additionally, unresolved debates about data ownership and informed consent create further complexity. These ethical challenges may weaken public trust and slow down the adoption and development of personalized medicine solutions worldwide.

Covid-19 Impact:

The COVID-19 outbreak significantly influenced the personalized medicine market by speeding up the use of advanced healthcare solutions. The urgent need to track virus variations and understand individual patient responses increased reliance on genomic sequencing, rapid testing, and targeted therapeutic strategies. Governments and health systems invested more in precision medicine technologies to support vaccine research and disease monitoring. The pandemic also boosted the use of data analytics and biotechnology in healthcare decision-making. However, interruptions in clinical studies, supply networks, and routine medical services caused temporary setbacks. Despite these challenges, the crisis ultimately enhanced the long-term growth outlook for personalized medicine worldwide.

The personalized diagnostics segment is expected to be the largest during the forecast period

The personalized diagnostics segment is expected to account for the largest market share during the forecast period as it plays a vital role in identifying diseases at an early stage and supporting effective treatment decisions. This segment involves analyzing genetic data, biomarkers, and molecular indicators to better understand individual health conditions and risks. The growing use of advanced diagnostic technologies, including genomic testing, imaging systems, and companion diagnostic tools, has enhanced its market position. Increasing focus on preventive healthcare and the need for precise, timely diagnosis are also driving its growth. By providing essential insights for targeted therapies, personalized diagnostics serves as the core of precision medicine and improves patient outcomes significantly.

The research & academic institutes segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the research & academic institutes segment is predicted to witness the highest growth rate because they play a key role in innovation and scientific advancement. These organizations are heavily involved in studying genomics, identifying biomarkers, and conducting clinical research that supports precision medicine development. Growing financial support from governments and private entities is enabling expansion of research activities in fields like genomics, proteomics, and bioinformatics. Strong collaboration with pharmaceutical and biotechnology companies is helping accelerate the development of personalized treatments. Additionally, the emphasis on converting research findings into real clinical applications is driving strong growth in this segment worldwide.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare system, rapid adoption of innovative technologies, and strong investment in research activities. The region is home to major pharmaceutical and biotechnology firms, along with highly developed genomic research facilities and supportive regulatory policies. The United States significantly contributes through widespread use of precision diagnostics and individualized therapies. Additionally, government support and funding for genomic research initiatives strengthen the region's leadership position, making North America the key market for personalized medicine globally.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR because of rapid healthcare system development, rising medical spending, and increasing awareness of precision healthcare solutions. The growing burden of chronic illnesses in major countries like China, India, and Japan is boosting the need for advanced diagnostics and customized therapies. Strong investments in biotechnology, genomics, and digital healthcare technologies are further enhancing growth. Government programs supporting healthcare innovation and modernization are also contributing significantly. Moreover, the region's large population base and expanding clinical research activities make it a key growth hub for personalized medicine adoption.

Key players in the market

Some of the key players in Personalized Medicine Market include F. Hoffmann-La Roche Ltd, Illumina, Inc., Thermo Fisher Scientific Inc., Novartis AG, Pfizer Inc., Abbott Laboratories, Qiagen, GE Healthcare, Inc., AbbVie Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Gilead Sciences, Inc., AstraZeneca, Sanofi, Takeda Pharmaceutical Company Ltd., Amgen Inc., Merck & Co., Inc. and Guardant Health.

Key Developments:

In April 2026, GE HealthCare announced an expanded collaboration with DeepHealth, Inc, to further the innovation, commercialization, and adoption of advanced AI-powered mammography tools. The announcement coincides with the Society of Breast Imaging (SBI) Annual Symposium, where GE HealthCare will showcase its latest advancements in breast imaging and women's health.

In November 2025, Abbott and Exact Sciences announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.

In May 2025, Novartis has signed a strategic agreement with Shanghai Pharma to help sell the Swiss company's mature ophthalmic products in China. Novartis will leverage Shanghai Pharma's omni-channel integrated marketing services and broad market coverage capabilities to accelerate the reach of some Novartis drugs for ocular infections and glaucoma in smaller territories not currently targeted by Novartis.

Products Covered:

• Personalized Therapeutics
• Personalized Diagnostics
• Personalized Care Solutions

Technologies Covered:

• Genomics & Sequencing
• Pharmacogenomics
• Proteomics & Metabolomics
• Digital Health & AI Integration
• Biomarker Analysis

Applications Covered:

• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Rare & Genetic Disorders

End Users Covered:

• Hospitals & Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Pharmaceutical & Biotech Companies

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Personalized Medicine Market, By Product

• 5.1 Personalized Therapeutics
• 5.2 Personalized Diagnostics
• 5.3 Personalized Care Solutions

6 Global Personalized Medicine Market, By Technology

• 6.1 Genomics & Sequencing
• 6.2 Pharmacogenomics
• 6.3 Proteomics & Metabolomics
• 6.4 Digital Health & AI Integration
• 6.5 Biomarker Analysis

7 Global Personalized Medicine Market, By Application

• 7.1 Oncology
• 7.2 Neurology
• 7.3 Cardiology
• 7.4 Infectious Diseases
• 7.5 Rare & Genetic Disorders

8 Global Personalized Medicine Market, By End User

• 8.1 Hospitals & Clinics
• 8.2 Diagnostic Laboratories
• 8.3 Research & Academic Institutes
• 8.4 Pharmaceutical & Biotech Companies

9 Global Personalized Medicine Market, By Geography

• 9.1 North America
  • 9.1.1 United States
  • 9.1.2 Canada
  • 9.1.3 Mexico
• 9.2 Europe
  • 9.2.1 United Kingdom
  • 9.2.2 Germany
  • 9.2.3 France
  • 9.2.4 Italy
  • 9.2.5 Spain
  • 9.2.6 Netherlands
  • 9.2.7 Belgium
  • 9.2.8 Sweden
  • 9.2.9 Switzerland
  • 9.2.10 Poland
  • 9.2.11 Rest of Europe
• 9.3 Asia Pacific
  • 9.3.1 China
  • 9.3.2 Japan
  • 9.3.3 India
  • 9.3.4 South Korea
  • 9.3.5 Australia
  • 9.3.6 Indonesia
  • 9.3.7 Thailand
  • 9.3.8 Malaysia
  • 9.3.9 Singapore
  • 9.3.10 Vietnam
  • 9.3.11 Rest of Asia Pacific
• 9.4 South America
  • 9.4.1 Brazil
  • 9.4.2 Argentina
  • 9.4.3 Colombia
  • 9.4.4 Chile
  • 9.4.5 Peru
  • 9.4.6 Rest of South America
• 9.5 Rest of the World (RoW)
  • 9.5.1 Middle East
    • 9.5.1.1 Saudi Arabia
    • 9.5.1.2 United Arab Emirates
    • 9.5.1.3 Qatar
    • 9.5.1.4 Israel
    • 9.5.1.5 Rest of Middle East
  • 9.5.2 Africa
    • 9.5.2.1 South Africa
    • 9.5.2.2 Egypt
    • 9.5.2.3 Morocco
    • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

• 10.1 Industry Value Network and Supply Chain Assessment
• 10.2 White-Space and Opportunity Mapping
• 10.3 Product Evolution and Market Life Cycle Analysis
• 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

• 11.1 Mergers and Acquisitions
• 11.2 Partnerships, Alliances, and Joint Ventures
• 11.3 New Product Launches and Certifications
• 11.4 Capacity Expansion and Investments
• 11.5 Other Strategic Initiatives

12 Company Profiles

• 12.1 F. Hoffmann-La Roche Ltd
• 12.2 Illumina, Inc.
• 12.3 Thermo Fisher Scientific Inc.
• 12.4 Novartis AG
• 12.5 Pfizer Inc.
• 12.6 Abbott Laboratories
• 12.7 Qiagen
• 12.8 GE Healthcare, Inc.
• 12.9 AbbVie Inc.
• 12.10 Eli Lilly and Company
• 12.11 Bristol-Myers Squibb Company
• 12.12 Gilead Sciences, Inc.
• 12.13 AstraZeneca
• 12.14 Sanofi
• 12.15 Takeda Pharmaceutical Company Ltd.
• 12.16 Amgen Inc.
• 12.17 Merck & Co., Inc.
• 12.18 Guardant Health